Thus, several clinical trials were launched just recently in order to prevent ARDS and mortality of COVID-19 by C5a inhibitor (Zilucoplan, NCT04382755) or anti-C5a antibody (Eculizumab, NCT04288713). The gene discussed is C5; the disease is acute respiratory distress syndrome.